针对减毒活登革热疫苗产生的抗体在激活补体系统方面具有功能性
研究分析了2期临床试验DEN-203中受试者接种武田登革热候选疫苗TAK-003前后的血清,用Luminex多重免疫分析检测针对4种登革病毒血清型的补体固定抗体。结果显示TAK-003可诱导产生补体固定抗体并持续1年,且与中和抗体滴度及病毒结合总IgG和IgG1浓度相关。
要点
- TAK-003诱导针对全部4种登革病毒血清型的补体固定抗体,接种后持续1年。
- 补体固定抗体水平与中和抗体滴度及病毒结合总IgG和IgG1浓度相关。
- 多克隆IgG亲和力较高的样本补体固定效率更高。
核心结论
- TAK-003接种后产生的抗体既能激活补体系统,也能中和全部登革病毒血清型的感染,可能有助于TAK-003的效力。
研究设计与样本
- 研究采集2期临床试验DEN-203中血清阴性和血清阳性参与者的接种前和接种后血清样本。
- 采用基于Luminex的多重免疫分析评估针对登革病毒的补体固定抗体。
主要发现
- TAK-003诱导产生针对全部4种登革病毒血清型的补体固定抗体,无论基线血清状态如何,接种后持续1年。
- 补体固定抗体水平与中和抗体滴度及病毒结合总IgG和IgG1浓度相关。
- 多克隆IgG亲和力较高的样本中补体固定效率更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibody-driven complement system (CS) activation has been associated with protection against symptomatic dengue virus (DENV) infection. Aggregation, opsonization, lysis, and phagocytosis are mechanisms triggered by antibody-antigen immunocomplexes following fixation of the component 1q (C1q) and activation of the classical pathway. As a result, DENV neutralization and clearance are facilitated, whereas antibody-dependent enhancement of infection is inhibited. We investigated the ability of antibodies produced in response to Takeda's dengue vaccine candidate, TAK-003, to fix C1q and activate CS. METHODS: Serum samples were collected from seronegative and seropositive participants in a phase 2 clinical trial (DEN-203), pre- and postvaccination. Samples were evaluated for the presence of complement-fixing antibodies (CFAs) against DENV using a Luminex multiplex-based immunoassay. RESULTS: TAK-003 elicited production of CFAs against all 4 DENV serotypes, which persisted for 1 year postvaccination, irrespective of baseline serostatus. CFA levels were correlated with neutralizing antibody titers and virus-binding total IgG and IgG1 concentrations. Furthermore, efficiency of CFA fixation was greater in samples with higher polyclonal IgG avidity. CONCLUSIONS: These results indicate that antibodies produced after TAK-003 vaccination are functional in both activating CS and neutralizing virus infection by all DENV serotypes, which may contribute to efficacy of TAK-003. CLINICAL TRIALS REGISTRATION: NCT01511250.
引用
- Nascimento EJM, Norwood B, Kpamegan E, et al. Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System. J Infect Dis. 2023. PMID: 36461942. doi:10.1093/infdis/jiac476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。